Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase III CheckMate-548 study does not meet one of its primary endpoints

Sep. 6, 2019

Patient enrollment ongoing in phase I study of Debio-0123

Sep. 6, 2019

FDA grants IND approval for HH-2710

Sep. 6, 2019

Circulating galectin-1 as a predictive biomarker of CAD and MACE in patients with stable angina

Sep. 6, 2019

CAD-1883 demonstrates promising safety in phase I study

Sep. 6, 2019

Potent AXL kinase inhibitor with promising in vitro and in vivo biological activity

Sep. 6, 2019

An organoid model for prenatal brain development

Sep. 6, 2019

Dystrophy mutation protects cells from HIV infection

Sep. 6, 2019

ADC traffic rules revealed

Sep. 6, 2019

New trials evaluate IPI-549 in combination therapies for solid tumors

Sep. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.